A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Clinical trial NCT07299019 · RECRUITING

Trial details

NCT number: NCT07299019
Sponsor: Zenas BioPharma (USA), LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Secondary Progressive Multiple Sclerosis

Start date: 2026-03-23
Primary completion: 2030-06-01
Enrollment: 990

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.